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Introduction
Familial Mediterranean Fever (FMF) is a disease character-
ized by attacks and colchicine is the medication consid-
ered most effective in reducing the intensity and frequency
of attacks. Adherence to the medication regiment is
important not only to manage FMF symptoms, but also to
prevent amyloidosis.
Objective
In this study, it is aimed to develop and assess the valid-
ity and reliability of the adherence scale for colchicine
treatment in pediatric FMF patients.
Methods
This study was planned as a methodological study to
development of scale for assessment of adherence to treat-
ment of pediatric patients with FMF using colchicine
treatment. Pediatric patients (2-18 ages) with FMF using
colchicine at least 6 months and accepted to participate in
the study constitute the sample of the study. “Data collec-
tion forms about the sociodemographic and medical infor-
mation (demographic, clinical and laboratory findings) of
patients”, “adherence scale for colchicine in pediatric FMF
patients” and “Morisky Medication Adherence Scale” were
used as data collection instruments. If the patient was
under 7 years old, his parents filled the forms.
Results
There were 150 patients with FMF enrolled for the valida-
tion of the study. The median age of the patients was
11.11±4.02 (min.2.74-max.17.99) and 48.7% of them were
male. The median of the attack frequency was
11,00±10,74(min. 0-max 52) and 60.7% of the participants
had irregular attacks.
For internal consistency, Cronbach’s alpha was 0,728
for “adherence scale for colchicine in pediatric FMF
patients”. Also, there was a positive and significant cor-
relation (r: 0.843, p
Conclusion
Based on these results, using this scale for the purpose
of the assessment and follow up of adherence to treat-
ment of pediatric patients with FMF who use colchicine
is recommended.
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